The Division of Clinical Haematology, in partnership with the UCT Clinical Research Centre, runs various clinical trials at Groote Schuur Hospital. Our collaborative efforts aim to advance treatments for various diseases and provide patients with the opportunity to access novel treatments that are in development.

The current clinical trials investigate the treatment of immune thrombocytopenic purpura (ITP), paroxysmal nocturnal haemoglobinuria (PNH), and haematological malignancies including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and specific non-hodgkin lymphomas including follicular lymphoma and diffuse large B-cell lymphoma. Please contact Dr. Fiona Watt (fiona.watt@uct.ac.za) or Dr. Gerdien Kritzinger (gerdien.kritzinger@uct.ac.za) if you would like any further information about the following trials that are currently screening new patients for potential enrolment:

  1. BCX10013-105: An Open-label, Multicenter, Intra-subject Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential of BCX10013 in Subjects with Paroxysmal Nocturnal Haemoglobinuria
  2. MK1026-008: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations 
  3. M20-638: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma
  4. M20-621: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
  5. MK1026-010: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy.